Search

  5. ProQR Announces Second Quarter 2023 Operating and Financial Results

    Press release

    Divestment of sepofarsen and ultevursen ophthalmic programs supports ProQR’s strategic focus on Axiomer® RNA editing platform technology and continued advancement of pipeline €129 M cash and cash equivalents as of June 30, 2023 providing runway into mid-2026

  6. Presentations & Publications

    Page

    Find all relevant presentations and publications for each of our programs. From review papers to preclinical posters and clinical data presentations at medical conferences.

    Scientist working in ProQR's laboratories

  7. Partnerships

    Page

    ProQR has collaborations with important names in the industry including Eli Lilly and Company. Read more about our partnerships.

    A ProQRian working on a cell culture in the laboratory

  8. Careers

    Page

    … offices in Leiden we are advancing our proprietary Axiomer RNA-editing platform technology. Our ProQRians, representing over …

    A meeting of ProQRians

  9. About ProQR Therapeutics

    Page

    An innovative biotech company advancing our proprietary Axiomer RNA-editing platform technology.

    Female scientist working in ProQR's laboratories